Navigation Links
IDRI and Zydus sign agreement for development of IDRI's vaccine candidate for visceral leishmaniasis
Date:7/25/2013

Seattle, WA, and Ahmedabad, India, July 25, 2013: In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis (VL) vaccine candidate, designed to prevent the deadly parasitic disease.

Known as Kala-Azar in India, VL is transmitted by the bite of an infected sand fly. There are over 500,000 new VL cases and 50,000 associated deaths each year. VL is the most severe form of leishmaniasis, affecting vital organs and, if left untreated, the disease can be fatal. A vaccine is considered essential to control and eliminate the disease. Currently, leishmaniasis occurs in four continents and is considered to be endemic in 88 countries; 72 of those are developing countries, with the disease being most common in India, Nepal, Bangladesh, Sudan and Brazil. While there are drugs to treat the disease, they are expensive and often toxic. To date, a safe and efficacious vaccine to prevent this disease does not exist.

Zydus and IDRI will collaborate to conduct clinical activities in India with the goal of developing, registering and marketing this vaccine candidate for the prevention of VL, while achieving the objective of global access that is, ensuring the vaccine is affordable to and accessible by all people in need. Conducting trials in India, where there are real-life situations of disease exposure, is critical to determining the effectiveness of the IDRI's VL vaccine candidate and ensuring it is approved and available within endemic countries.

IDRI's VL vaccine candidate, LEISH-F3+GLA-SE, is the product of more than 20 years of research and development supported by the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation. The defined, purified, recombinant vaccine is comprised of two fused Leishmania parasite proteins and an adjuvant to stimulate a protective immune response against the parasite. After completion of a Phase 1 clinical trial of 36 U.S. adult volunteers to test safety and immunogenicity, the vaccine was shown to be safe and to induce potent immune responses in healthy volunteers.

Speaking of the partnership, Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus group, said, "Zydus has always been committed to working with partners and collaborating to bridge unmet healthcare needs. By partnering with IDRI on this very important mission, we will be taking an all important step to eradicate visceral leishmaniasis, which is a huge healthcare burden."

Dr. Steven G. Reed, IDRI Founder and President added, "Zydus' expertise and breadth of development and commercialization experience will be instrumental in getting IDRI's VL vaccine to the people who need it most. We are appreciative of Zydus' commitment to this program. This is an excellent example of cooperating to help combat a devastating disease without consideration for a profit motive. IDRI could not ask for a better partner in this endeavor."


'/>"/>

Contact: Lee Schoentrup
lee.schoentrup@idri.org
206-858-6064
Infectious Disease Research Institute
Source:Eurekalert

Related biology news :

1. Eurofins MWG Operon and Floragenex close co-marketing agreement for RAD discovery and RAD genotyping
2. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
3. Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement
4. Psychemedics & TruTouch Announce US Sales/Marketing Distribution Agreement For TruTouch Technologies Rapid Optical Alcohol Detection & Biometric Test
5. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
6. University of Colorado and Orphan Technologies sign agreement
7. RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
8. Ukraine, EU Advance on Visa Facilitation Agreement
9. CHOP and BGI strengthen partnership with agreement on pediatric brain tumor collaboration
10. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
11. Wiley signs collaboration agreement with the Asian Federation of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... 2017 (PRWEB) , ... June ... ... of Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics (CFD) simulation and ... exploration and optimization. STAR-CCM+ version 12.04 introduces Design Manager, allowing users to ...
(Date:6/27/2017)... ... June 27, 2017 , ... Brain State Technologies, ... Kickstarter campaign on June 15th to fund production of the new B2v2 wearable ... original Kickstarter goal by more than 150% in a little over a week. ...
(Date:6/27/2017)... ... June 27, 2017 , ... DuPont ... gains exclusive rights to the ERS patent portfolio covering CRISPR-Cas genome editing technology ... the foundational intellectual property (IP) of the CRISPR-Cas technology from co-inventor and co-owner ...
(Date:6/26/2017)... ... , ... Two new members were elected to the University City Science Center’s ... President, J Nowak Strategy and Michele Masucci, Ph.D., Vice President for Research Administration at ... and Kenneth L. Kring, and re-election of David P. Holveck and Richard P. Jaffe, ...
Breaking Biology Technology: